Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 648

Results For "ED"

9532 News Found

AlloVir appoints Derek Adams to Board of Directors
People | February 27, 2023

AlloVir appoints Derek Adams to Board of Directors

Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.


Pfizer’s Elranatamab receives FDA and EMA filing acceptance
Drug Approval | February 25, 2023

Pfizer’s Elranatamab receives FDA and EMA filing acceptance

Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma


EMA recommends refusal of the marketing authorization for Lagevrio
News | February 25, 2023

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.


SERDA therapeutics submits IND for wound debridement agent
Drug Approval | February 24, 2023

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.


Novartis appoints Gilbert Ghostine Chairman-Designate of Sandoz Board of Directors
News | February 24, 2023

Novartis appoints Gilbert Ghostine Chairman-Designate of Sandoz Board of Directors

Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.


Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr
News | February 24, 2023

Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr

The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022


MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates
Clinical Trials | February 24, 2023

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months


Briefs: Alkem and Krsnaa Diagnostics
News | February 24, 2023

Briefs: Alkem and Krsnaa Diagnostics

Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.